NANOMICRO(SH:688690)2024-02-05 07:36Group 1: Investor Relations Activities - The investor relations activities included online meetings and discussions on performance forecasts, equity incentives, product development, and market expansion [1]. - Participants included representatives from various financial institutions such as CITIC Securities, East Money Global Fund, and others [1]. Group 2: Performance Forecast and Incentives - The new restricted stock incentive plan for 2024 is set at 950 million CNY, with approximately 30% of the growth expected from the acquisition of Fuli Instruments, which is projected to add 200 million CNY in consolidated revenue [1]. - The company aims to achieve significant growth in 2023, driven by the commercialization of new drug projects and increased demand for peptide and nucleic acid drug development [1]. Group 3: Business Development and Market Expansion - The core business of chromatography fillers and media is expected to see growth, although the antibody project market recovery may take time [1]. - The company plans to complete the consolidation of Fuli Instruments in Q1 2024, leveraging synergies between Fuli Instruments and NAPU Analysis for enhanced technical development and market sales [1].